Aegis

Aegis Life is a biotechnology company dedicated to developing the next generation of genetic medicines, including vaccines and therapies for infectious diseases and other conditions. The company leverages the proprietary Fusogenix proteo-lipid vehicle (PLV) platform, licensed from Entos Pharmaceuticals, which utilizes a unique fusion mechanism to deliver genetic payloads directly into target cells. This platform is designed to overcome the limitations of traditional lipid nanoparticles by providing enhanced stability, lower toxicity, and the ability to be redosed. Aegis Life's lead programs have focused on developing a needle-free, room-temperature stable DNA vaccine for COVID-19 and other respiratory viruses.